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MacEwen et al. aministered to dogs with oral malignant 
melanoma L-MTP-PE alone or in combination with 
recombinant canine granulocyte macrophage colony-
stimulating factor (GM-CSF). In early stages, the 
treatment showed a prolongation of survival time. 
However, there was no significant antitumor activity in 
advanced stages of canine oral melanoma. 
Bianco et al. examined apoptosis of canine melanoma 
cells lines in vitro by overexpression of FasL DNA. 
Overexpression of FasL induced apoptosis in each of 
five Fas+ canine melanoma cell lines whereas Fas- cell 
line was resistant. Direct intratumoral administration of 
FasL DNA to dogs with melanoma was safe and a 
tumoral regression was seen in three out of five dogs. 
In the study of Westberg et al., dogs with spontaneous 
melanoma were locally infected with a recombinant 
adenovirus vector expressing human CD40L. 68% of the 
patients had a tumor regression higher than 50%, with 
26% of them having a complete regression. Tumor tissue 
was infiltrated with T and B lymphocytes and treatment 
was safe. 
Helfand et al. examined the ability of a low dose of 
human recombinant IL-2 to enhance tumoricidal 
properties of canine peripheral blood lymphocytes (PBL) 
in vitro. Human recombinant IL-2 could significantly 
increase tumor cytotoxicity mediated by canine PBL in 
vitro, even when used at a concentration unlikely to 
induce in vivo toxicity in dogs. 
Dow et al. treated locally dogs with spontaneous 
melanoma with plasmid DNA encoding staphylococcal 
enterotoxin B and either GM-CSF or IL-2.  46% of dogs 
had complete or partial response. Tumor tissue was 
infiltrated with macrophages and T lymphocytes. There 
were increased levels of cytotoxic CD8+ lymphocytes in 
the bloodstream. Increased survival time was observed 
and treatment was safe. 
Helfand, Soergel, Donner et al. assessed the ability of 
monoclonal antibodies (Mab) targeting GD2 to mediate 
antibody-dependent cellular cytotoxicity in vitro against 
a canine melanoma cell line (CML-10). Monoclonal 
antibodies potentiated lysis of the canine melanoma cell 
line by canine peripheral blood lymphocyte (PBL) 
stimulated with IL-2. 
Finocciaro et al. treated dogs with melanoma with 
intratumoral injections of a plasmid encoding herpes 
simplex thymidine kinase (HSVtk) coadministrated with 
ganciclovir (GCV), and irradiated xenogeneic cells 
secreting GM-CSF and IL-2. 16% of cases had complete 
response and 31% had partial response, with an average 
of 80% of tumor regression. Treatment was safe and 
significantly improved median survival time.  
Laborda et al. treated nude mice bearing canine 
melanoma xenograft with a conditionally replicative 
adenovirus (a canine adenovirus type 2-based oncolytic 
virus). Treatment resulted in inhibition of tumor growth 
and prolonged survival of mice. Local administration of 
the same adenovirus in six tumor bearing dogs led to two 
partial responses. There was no direct virus associated 
adverse effects. 
Alexander et al. describe the development of an 
allogeneic whole-cell tumor vaccine (17CM98 canine 
melanoma cell line) transfected with xenogeneic human 
gp100. The overall response rate was 17% (3% complete 
response and 14% partial response). Dogs with evidence 
of tumor control had a median survival significantly 
longer (337 days). Treatment was well tolerated.  
Gyorffy et al. performed an ex vivo expansion of 
dendritic cells (DC) derived from bone marrow of three 
dogs with spontaneous melanoma. DC were transduced 
with the xenoantigen hgp100 and were used as a vaccine. 
A dog demonstrated antigen-specific cytotoxic T 
lymphocyte (CD8+) activity in peripheral blood 
lymphocytes. This dog had no signs of recurrent disease 
48 months after initial vaccine injection. 
Two important studies with opposite conclusions 
examined the efficacy of a vaccine containing plasmid 
DNA encoding human tyrosinase. In the Grosenbaugh et 
al. paper, the use of the vaccine significantly increased 
survival times. The melanoma specific median survival 
time was not reached. In the Ottnod et al. study, the 
vaccine did not improve the progression free survival, 
disease-free interval or median survival time. 
This picture, modified from Regan et al., shows the 
mechanism of action of monoclonal antibodies against 
CTLA-4 (ipilimumab) and PD-1 (lambrolizumab). This 
immunotherapies have not yet been studied in canine 
malignant melanoma. 
FACULTAT DE VETERINÀRIA 
This picture shows the procedure of adoptive cell 
therapy. This immunotherapy has not yet been studied in 
canine malignant melanoma. 
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CONCLUSION 
The field of tumor immunotherapy is growing rapidly. Melanoma vaccination is having an impressive progress, with new approaches 
incorporating new antigen targets and delivery technologies. Recent immunotherapeutic advances against melanoma have been made in 
human medicine, including anti-CTLA-4 and anti-PD-1 antibodies and adoptive T-cell transfer. Hopefully, in a future, veterinary 
oncologists will have access to these innovative and effective immunotherapies.  
Further research is needed to: 
• Understand why some immunotherapies are only effective in some patients  
• Improve the immunotherapeutic modalities (maximize efficacy, minimize toxicity and avoid resistance mechanisms) 
• Detect reliable biomarkers (e.g. PD-L1) to increase the proportion of patients responding to immunotherapy 
• Determinate the most effective immunotherapeutic combinations (potential synergistic activity) 
INTRODUCTION AND OBJECTIVES 
Canine malignant melanoma is a spontaneous and highly aggressive tumor of the oral cavity, digit and mucocutaneous junctions which is similar biologically to malignant melanoma in 
humans. Following conventional treatments (surgery, radiation therapy and/or chemotherapy), median survival times range from 4 to 12 months. Therefore, new strategies to treat canine 
melanoma are warranted. In the past decade, the rapidly advancing field of cancer immunology has produced several new immunotherapies for treating cancer that increase the strength of 
immune system against tumors. The objective of this work is the accomplishment of a bibliographic review to understand the mechanisms of action of the different immunotherapeutic 
strategies developed against canine malignant melanoma, and to review their effectiveness. The different immunotherapeutic strategies have been classified into four sections: innate 
immunotherapy, specific immunotherapy, vaccination and future prospects. 
